WALTHAM, Mass. and VIENNA--(BUSINESS WIRE)--Nov. 20, 2017--
Arsanis, Inc. (NASDAQ:ASNS), a clinical-stage biopharmaceutical company
focused on applying monoclonal antibody immunotherapies to address
serious infectious diseases, today announced the closing of its initial
public offering of 4,600,000 shares of its common stock at a public
offering price of $10.00 per share, including 600,000 additional shares
of common stock issued upon the exercise in full by the underwriters of
their over-allotment option. The gross proceeds to Arsanis from the
offering were $46.0 million, before deducting underwriting discounts and
commissions and other offering expenses. All of the shares sold in the
offering were offered by Arsanis. Arsanis’ shares began trading on The
NASDAQ Global Market on November 16, 2017.
In addition, a fund affiliated with New Enterprise Associates purchased
$20.0 million of Arsanis' common stock in a separate private placement
concurrent with the completion of Arsanis' initial public offering at a
price per share equal to the initial public offering price.
Citigroup, Cowen and Piper Jaffray & Co. acted as joint book-running
managers for the public offering and as placement agents for the
concurrent private placement.
A registration statement relating to the securities offered and sold in
the initial public offering was filed with, and declared effective by,
the Securities and Exchange Commission. Copies of the registration
statement can be accessed by visiting the Securities and Exchange
Commission website at www.sec.gov.
This offering was made only by means of a prospectus. A copy of the
final prospectus relating to the offering was filed with the Securities
and Exchange Commission and may be obtained from Citigroup Global
Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island
Avenue, Edgewood, NY 11717, or by telephone at (800) 831-9146; Cowen and
Company, LLC, c/o Broadridge Financial Solutions, Attention: Prospectus
Department, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone
at (631) 274-2806; or Piper Jaffray & Co., Attention: Prospectus
Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by
telephone at (800) 747-3924, or by email at email@example.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of, these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of such state or jurisdiction.
Arsanis, Inc. is a clinical-stage biopharmaceutical company focused on
applying monoclonal antibody (mAb) immunotherapies to address serious
infectious diseases. A deep understanding of the pathogenesis of
infection, paired with access to some of the most advanced mAb discovery
techniques and platforms available today, has positioned Arsanis to
build and advance a pipeline of novel mAbs with multiple mechanisms of
action and high potency against their intended targets. The company’s
lead clinical program, ASN100, is aimed at serious Staphylococcus
aureus infections and is being evaluated in a Phase 2 clinical trial
for the prevention of S. aureus pneumonia in high-risk,
mechanically ventilated patients. In addition to ASN100, its preclinical
pipeline is comprised of mAbs targeting multiple serious bacterial and
viral pathogens, including respiratory syncytial virus.
Arsanis is a U.S. company headquartered in Waltham, Massachusetts, with
European research and preclinical development operations headquartered
in Vienna, Austria (Arsanis Biosciences GmbH).
View source version on businesswire.com: http://www.businesswire.com/news/home/20171120006068/en/
Source: Arsanis, Inc.
Ten Bridge Communications
Michael Gray, 781-819-5201
Chief Operating and
Chief Financial Officer